NCT05141357 2025-12-24
HBI-8000
HUYABIO International, LLC.
Phase 2 Terminated
Clinical Trials
7 trialsNCT05833724 2025-03-11
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Great Novel Therapeutics Biotech & Medicals Corporation
Phase 2 Recruiting
NCT02953652 2024-09-19
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
HUYABIO International, LLC.
Phase 2 Completed
NCT02955589 2024-09-19
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
HUYABIO International, LLC.
Phase 2 Completed
NCT03201471 2018-08-02
DLBCL
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT03605056 2018-07-30
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT03336632 2018-07-18
Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT
Sichuan University
Phase 2 Unknown